Press Releases

Press Releases

Date	Title
May 17, 2025	AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
May 12, 2025	Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
May 05, 2025	Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
May 01, 2025	Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Apr 28, 2025	Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Apr 17, 2025	Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
Apr 01, 2025	Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
Mar 29, 2025	Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
Mar 28, 2025	FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Mar 20, 2025	Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

For Media Inquiries, please contact:

Christine Lindenboom

Chief Corporate Communications Officer media@alnylam.com 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276

MEDIA KIT

Essential assets and documents related to Alnylam

Looking for specific information that isn't listed above?